Letter

Somatostatin in gastroenterology More studies needed

BMJ 1994; 309 doi: 10.1136/bmj.309.6954.604 (Published 3 September 1994)
Cite this as: BMJ 1994;309:604

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. G L Carlson,
  2. N A Scott,
  3. M H Irving,
  4. J J Sancho,
  5. A Sitges-Serra
  1. University of Manchester, Hope Hospital, Salford M6 8HD Department of Surgery, Hospital Universitari del Mar, P Maritim 25-29, 08003 Barcelona, Spain
  2. University of Melbourne, Department of Surgery, Austin Hospital, Heidelberg, Victoria 3084, Australia Department of Gastroenterology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.

    EDITOR, - We noted with concern the enthusiasm with which A Shulkes and J S Wilson endorse the use of somatostatin and its analogue octreotide in gastroenterology.1 In particular, we have reservations concerning the reported role of octreotide in the management of enterocutaneous fistula since, despite a successful pilot study,2 more studies seem warranted to clarify the timing and the cost-benefit of such treatment. Indeed, more recent studies of patients with such fistulas have failed …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular